Gene Predictis moves into top gear

Please login or
register
06.09.2013

Gene Predictis is a pioneer in genetic testing. The start-up now has developed two products which turn the concept of personalised medicine from a slogan to reality.

Conventional medicine treats all the patients in the same way. As consequence, adverse drug effects are the fourth most important cause of death in the developed world. One third of all hospitalizations occur as the consequence of harmful drug-drug interactions or an inability to properly metabolize drugs. The answer to this problem is personlized medicine.

Gene Predictis is a pioneer in this field. It was founded in 2005, as one of the first genetic testing companies in Europe. Since last year the company increases sales rapidly. The team aims at a rapid growth for the next years too based on two products: Pill Protect, that is aiming at the prevention of thromboembolism associated with birth control pills, and Cypass for the optimization of drug prescription.

Pill Protect is the only test on the market that allows precise estimation of the thromboembolism risk by combining the genetic, the environmental, and the behavioural risk factors. The risk calculation is based on the proprietary algorithm that accounts the risk for each of the contraceptive pills sold on the Swiss and the European market. Pill Protect allows identifying the most optimal and the safest contraceptive pill/method for every woman.

Cypass provides with a very comprehensive overview on an individual's abilities to metabolize and eliminate drugs. It is based on genetic test and proprietary algorithms that allow truly personalized drug prescription, it allows establishing the most efficient and the safest drug prescription for each patient. This test is accompanied by the CypassPortal, a web-based platform that facilitates the use of the test results in the everyday medical practice. This decision support tool covers roughly 90% of all currently existing drugs and operates on all most commonly used browsers in Europe and North America. Due to its wide application field, the market size for Cypassis very significant.

Gene Predictis seeks to carry-out international pharmaco-economic studies for these two most promising products. These will support their large-scale commercial launch. Investors are welcome to take part in this venture.

Gene Predictis was founded in 2005. Its headquarters and laboratories are located at the Innovation Square of the Ecole Polytechnique Fédérale de Lausanne (EPFL).

0Comments

More news about

Gene Predictis SA

Company profiles on startup.ch

Gene Predictis SA

rss